SPDR S&P Biotech ETF (NYSEARCA:XBI) Shares Purchased by Hanson & Doremus Investment Management

Hanson & Doremus Investment Management boosted its stake in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 28.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,618 shares of the exchange traded fund’s stock after acquiring an additional 1,259 shares during the period. Hanson & Doremus Investment Management’s holdings in SPDR S&P Biotech ETF were worth $534,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Papp L Roy & Associates increased its stake in SPDR S&P Biotech ETF by 3.7% during the third quarter. Papp L Roy & Associates now owns 215,174 shares of the exchange traded fund’s stock valued at $16,407,000 after purchasing an additional 7,623 shares during the last quarter. Cumberland Advisors Inc. boosted its position in shares of SPDR S&P Biotech ETF by 2.5% in the 3rd quarter. Cumberland Advisors Inc. now owns 211,059 shares of the exchange traded fund’s stock valued at $16,093,000 after purchasing an additional 5,230 shares during the period. Whittier Trust Co. boosted its position in shares of SPDR S&P Biotech ETF by 0.7% in the 3rd quarter. Whittier Trust Co. now owns 202,074 shares of the exchange traded fund’s stock valued at $15,408,000 after purchasing an additional 1,486 shares during the period. Eaton Vance Management increased its stake in SPDR S&P Biotech ETF by 7.2% in the 2nd quarter. Eaton Vance Management now owns 172,573 shares of the exchange traded fund’s stock worth $15,136,000 after purchasing an additional 11,536 shares in the last quarter. Finally, Ilmarinen Mutual Pension Insurance Co purchased a new position in SPDR S&P Biotech ETF in the 3rd quarter worth about $12,696,000.

NYSEARCA XBI traded down $0.25 on Thursday, hitting $96.89. 152,166 shares of the company were exchanged, compared to its average volume of 6,213,054. SPDR S&P Biotech ETF has a twelve month low of $72.97 and a twelve month high of $98.79. The company’s 50 day moving average price is $95.11 and its 200-day moving average price is $85.74.

The company also recently announced a quarterly dividend, which was paid on Thursday, December 26th. Shareholders of record on Monday, December 23rd were issued a $0.0009 dividend. This represents a $0.00 annualized dividend and a dividend yield of 0.00%. The ex-dividend date of this dividend was Friday, December 20th.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Recommended Story: Range Trading

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.